Merck, an American multinational pharmaceutical company, completed the acquisition of Prometheus Biosciences, a clinical-stage biotechnology company, for $10.8bn. “The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is another example of Merck acting strategically and decisively when science and value align. Prometheus brings us a potential best-in-class candidate that creates an opportunity for us to transform treatment for patients with immune-mediated diseases. We are excited to welcome our Prometheus colleagues to Merck and we look forward to working together, driven by our common purpose of saving and improving lives," Robert M. Davis, Merck Chairman and CEO.